Preterm Birth and PROM Market

Preterm birth is a birth that takes place before 37weeks of pregnancy is completed. Premature rupture of membranes (PROM) is a common pregnancy complication and is one of the leading cause of preterm births. Preterm birth and premature rupture of membrane (PROM) testing is broadly segmented into preterm birth testing and premature rupture of membrane (PROM) testing. The preterm birth testing includes fetal fibronectin (fFN) test, Kleihauer blood test, complete blood count test, and c-reactive protein test; whereas PROM testing includes nitrazine test, ferning test, biomarker tests such as Placental Alpha Microglobulin-1 (PAMG-1) Test, IGFBP-1 (Insulin-Like Growth Factor Binding Protein-1) Test, and Alpha-Fetoprotein (AFP) Test.

According to WHO preterm birth is a global health issue with about 1.5 million preterm births each year.  Additionally, about 60% of preterm births occur in South Asia and sub-Saharan African countries. Thus, these untapped emerging markets are expected to offer potential growth opportunities to players operating in the market during the forecast period. However, low reliability of test results is likely to pose a challenge, inhibiting the growth of the market.